Niimi Akio, Fukunaga Koichi, Taniguchi Masami, Nakamura Yoichi, Tagaya Etsuko, Horiguchi Takahiko, Yokoyama Akihito, Yamaguchi Masao, Nagata Makoto
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Pulmonary Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Allergol Int. 2023 Apr;72(2):207-226. doi: 10.1016/j.alit.2023.02.006. Epub 2023 Mar 22.
Asthma is characterized by chronic airway inflammation, variable airway narrowing, and sensory nerve irritation, which manifest as wheezing, dyspnea, chest tightness, and cough. Longstanding asthma may result in airway remodeling and become intractable. Despite the increased prevalence of asthma in adults, asthma-associated deaths have decreased in Japan (0.94 per 100,000 people in 2020). The goals of asthma treatment include the control of symptoms and reduction of future risks. A functional partnership between physicians and patients is indispensable for achieving these goals. Long-term management with medications and the elimination of triggers and risk factors are fundamental to asthma treatment. Asthma is managed via four steps of pharmacotherapy ("controllers"), ranging from mild to intensive treatments, depending on disease severity; each step involves daily administration of an inhaled corticosteroid, which varies from low to high dosage. Long-acting β agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonists are recommended as add-on drugs. Allergen immunotherapy is a new option that is employed as a controller treatment. Further, as of 2021, anti-IgE antibody, anti-IL-5 and anti-IL-5 receptor α-chain antibodies, and anti-IL-4 receptor α-chain antibodies are available for the treatment of severe asthma. Bronchial thermoplasty can be performed for asthma treatment, and its long-term efficacy has been reported. Algorithms for their usage have been revised. Comorbidities, such as allergic rhinitis, chronic rhinosinusitis, chronic obstructive pulmonary disease, and aspirin-exacerbated respiratory disease, should also be considered during the treatment of chronic asthma. Depending on the severity of episodes, inhaled short-acting β agonists, systemic corticosteroids, short-acting muscarinic antagonists, oxygen therapy, and other approaches are used as needed ("relievers") during exacerbation.
哮喘的特征为慢性气道炎症、可变的气道狭窄和感觉神经刺激,表现为喘息、呼吸困难、胸闷和咳嗽。长期哮喘可能导致气道重塑并变得难以治疗。尽管成人哮喘患病率有所上升,但日本的哮喘相关死亡率有所下降(2020年为每10万人中有0.94人)。哮喘治疗的目标包括控制症状和降低未来风险。医生与患者之间的功能性合作关系对于实现这些目标必不可少。药物的长期管理以及消除触发因素和风险因素是哮喘治疗的基础。哮喘通过四个药物治疗步骤(“控制药物”)进行管理,根据疾病严重程度从轻度到强化治疗;每个步骤都涉及每日吸入不同剂量(从低到高)的皮质类固醇。长效β受体激动剂、白三烯受体拮抗剂、缓释茶碱和长效毒蕈碱拮抗剂被推荐作为附加药物。变应原免疫疗法是一种作为控制治疗的新选择。此外,截至2021年,抗IgE抗体、抗IL-5和抗IL-5受体α链抗体以及抗IL-4受体α链抗体可用于治疗重度哮喘。支气管热成形术可用于哮喘治疗,其长期疗效已有报道。其使用算法已修订。在慢性哮喘治疗期间,还应考虑合并症,如过敏性鼻炎、慢性鼻-鼻窦炎、慢性阻塞性肺疾病和阿司匹林诱发的呼吸道疾病。根据发作的严重程度,在病情加重时按需使用吸入短效β受体激动剂、全身用皮质类固醇、短效毒蕈碱拮抗剂、氧疗和其他方法(“缓解药物”)。